A Phase1b Clinical Study of the Oral PI3Kd Inhibitor, Linperlisib, in Patients with B-Cell Lymphomas

被引：1
|
作者：
Qiu, Lugui [1 ,2 ]
Li, Zhiming [3 ]
Huang, Yunhong [4 ]
Liu, Ligen [5 ]
Liu, Lihong [6 ]
Guo, Ye [7 ]
Deng, Lan [8 ]
Yang, Haiyan [9 ]
CA, Zhen, I [10 ,12 ]
Ye, Xu [11 ]
Wang, Zhen
Bao, Hanying [13 ]
Xu, Zusheng [13 ]
Zheng, Binghua [13 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Tianjin, Peoples R China
[3] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China
[4] Guizhou Med Univ, Dept Lymphoma, Affiliated Canc Hosp, Guiyang, Peoples R China
[5] Shanghai Jiao Tong Univ, Tongren Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China
[6] Hebei Med Univ, Dept Hematol, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[7] Tongji Univ, Shanghai Dongfang Hosp, Dept Med Oncol, Shanghai, Peoples R China
[8] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Hematol, Sch Med, Shanghai, Peoples R China
[9] Univ Chinese Acad Sci, Canc Hosp, Dept Lymphoma, Hangzhou, Peoples R China
[10] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China
[11] Guangzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Guangzhou, Peoples R China
[12] Linyi Canc Hosp, Linyi, Peoples R China
[13] Shanghai Yingli Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-148276
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3576
引用
收藏
页数：5
相关论文
共 50 条
  • [31] A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data
    Soumerai, Jacob D.
    Opat, Stephen
    Cheah, Chan Y.
    Lasica, Masa
    Verner, Emma
    Browett, Peter J.
    Chan, Henry
    Barca, Eva Gonzalez
    Hilger, James
    Fang, Yiqian
    Simpson, David
    Tam, Constantine S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S267 - S268
  • [32] Phase 3 study of oral lenalidomide as maintenance therapy for patients with B-cell chronic lyouphocylic leukemia (CLL).
    Chanan-Khan, Asher Alban Akmal
    Zaritskey, Andrey
    Egyed, Miklos
    Vokurka, Samuel
    Samoylova, Olga
    Schuh, Anna
    Simpson, David
    Mei, Jay M.
    Oliveira, Natalia
    Kong, Oliver
    Foa, Robin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Coastal: A phase 3 study of the PI3Kd inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL).
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Cunningham, David
    Yavrom, Sharon
    Huang, Wenying
    Gorbatchevsky, Igor
    Ribrag, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
    Tarantelli, Chiara
    Gaudio, Eugenio
    Kwee, Ivo
    Rinaldi, Andrea
    Bernasconi, Elena
    Cascione, Luciano
    Hillmann, Petra
    Stathis, Anastasios
    Carrassa, Laura
    Broggini, Massimo
    Stussi, Georg
    Fabbro, Doriano
    Beaufils, Florent
    Melone, Anna
    Bohnacker, Thomas
    Wymann, Matthias P.
    Wicki, Andreas
    Zucca, Emanuele
    Cmiljanovic, Vladimir
    Bertoni, Francesco
    CANCER RESEARCH, 2015, 75
  • [35] A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas
    Crump, Michael
    Andreadis, Charalambos
    Assouline, Sarit E.
    Rizzieri, David
    Copeland, Amanda
    Van Der Jagt, Richard H. C.
    Fox, Susan
    Reid, Gregory K.
    Besterman, Jeffrey M.
    Martell, Robert E.
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] CYCLIN D1 EXPRESSION IN B-CELL LYMPHOMAS: A COMPARATIVE STUDY
    Gladkikh, A.
    Potashnikova, D.
    Korneva, E.
    Khudoleeva, O.
    Vorobjev, I.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 516 - 516
  • [37] Pharmaocogenomic Characterization of MCL-1 Inhibitor Response and Resistance in Aggressive B-Cell Lymphomas
    Wang, Michelle
    Li, Tao
    Ren, Yuan
    Shah, Bijal
    Lwin, Tint
    Gao, Jing
    Shain, Kenneth H.
    Zhang, Wei
    Zhao, Xiaohong
    Tao, Jianguo
    BLOOD, 2020, 136
  • [38] PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
    Xu-Monette, Zijun Y.
    Zhou, Jianfeng
    Young, Ken H.
    BLOOD, 2018, 131 (01) : 68 - 83
  • [39] A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas
    Rutherford, Sarah C.
    Allan, John N.
    Ruan, Jia
    Furman, Richard R.
    Richards, Kristy
    Rodriguez, Amelyn
    Gololobova, Kseniya
    Garcia, Arcania
    Cerchietti, Leandro
    Marullo, Rossella
    Chen, Zhengming
    Santamala, Jennifer
    Shore, Tsiporah B.
    Phillips, Adrienne A.
    Mayer, Sebastian
    Hsu, Jingmei
    Gergis, Usama
    Senese, Silvia
    Ali-Shaw, Trisha
    Rahim, Riyaad
    van Besien, Koen
    Leonard, John P.
    Martin, Peter
    BLOOD, 2020, 136
  • [40] An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies
    Phillips, Tycel
    Ramchandren, Rod
    Wertheim, Michael S.
    Gutierrez, Martin E.
    Edenfield, William J.
    Dawkins, Fitzroy
    DeMarini, Doug J.
    Zhou, Li
    Yeleswaram, Swamy
    Newton, Robert C.
    Chen, Xuejun
    Forero-Torres, Andres
    BLOOD, 2016, 128 (22)
12345